高碳酸血症性ARDS患者标准与二氧化碳适配性肾替代治疗的随机对照先导试验(BigBIC)
这项在德国柏林夏里特大学医学院五个ICU开展的前瞻性随机对照先导试验,纳入机械通气、pCO2>7.33 kPa且接受枸橼酸局部抗凝CKRT的高碳酸血症性ARDS患者,1:1随机分为标准组(碳酸氢盐目标24 mmol/l)与pCO2适配性CKRT组(目标碳酸氢盐对应生理性肾脏代偿),研究时长6天。主要终点为72小时碳酸氢盐,干预组30.70 mmol/l(IQR 29.48; 31.93)显著高于对照组26.40 mmol/l(IQR 25.63; 26.88),p<0.0001。干预组更多患者接受潮气量<8 ml/kg预测体重的肺保护性通气。30天死亡率对照组10/16(63%)vs 干预组8/19(42%),p=0.26。作者认为将CKRT适配呼吸性酸中毒的生理性肾脏代偿似乎可行且安全,有潜力改善患者照护。
要点
- 高碳酸血症性ARDS(pCO2>7.33 kPa)接受CKRT者,pCO2适配性CKRT组72小时碳酸氢盐30.70 mmol/l(IQR 29.48; 31.93)显著高于标准组26.40 mmol/l(IQR 25.63; 26.88),p<0.0001。
- 干预组更多患者接受潮气量<8 ml/kg预测体重的肺保护性通气。
- 30天死亡率标准组10/16(63%)vs pCO2适配组8/19(42%),p=0.26。
- 作者认为将CKRT适配呼吸性酸中毒的生理性肾脏代偿似乎可行且安全。
- 本研究为先导试验,共40例随机、分析35例,结论需进一步验证。
适用人群与场景
- 德国柏林夏里特大学医学院五个ICU中接受机械通气的成人高碳酸血症性ARDS患者,pCO2>7.33 kPa,且接受基于枸橼酸局部抗凝(RCA)的CKRT。
- 排除:随机后未接受治疗者不纳入分析,包括撤回知情同意、不符合纳入标准、突发意外死亡。
诊断标准与关键阈值
- 高碳酸血症界定:pCO2>7.33 kPa。
- 标准组碳酸氢盐目标24 mmol/l;pCO2适配性CKRT组目标碳酸氢盐对应生理性肾脏代偿。
- 肺保护性通气定义:潮气量<8 ml/kg预测体重。
处置流程与药物剂量
- CKRT采用枸橼酸局部抗凝(RCA)。
- 标准组:碳酸氢盐目标24 mmol/l。
- pCO2适配性CKRT组:目标碳酸氢盐对应呼吸性酸中毒的生理性肾脏代偿。
- 研究时长6天,主要终点为随机后72小时碳酸氢盐。
研究设计与关键结果
- 前瞻性随机对照先导试验,五个ICU,2021年9月至2023年5月纳入40例(80%男性),随机1:1:标准组19例、pCO2适配性CKRT组21例;5例在治疗前被排除(标准组3例:撤回知情同意、不符合纳入标准n=2;干预组2例:不符合纳入标准、突发意外死亡),未纳入分析,终点在全部接受治疗的患者中评估。
- 主要终点:随机后72小时血浆碳酸氢盐中位数干预组30.70 mmol/l(IQR 29.48; 31.93)vs 对照组26.40 mmol/l(IQR 25.63; 26.88),p<0.0001。
- 干预组更多患者接受潮气量<8 ml/kg预测体重的肺保护性通气。
- 30天死亡率:对照组10/16(63%)vs 干预组8/19(42%),p=0.26。
证据类型、等级与局限
- 证据类型:前瞻性随机对照先导试验(pilot trial)。
- 试验注册:德国临床试验注册(DRKS00026177),2021年9月9日注册。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,将CKRT适配呼吸性酸中毒的生理性肾脏代偿似乎可行且安全,有潜力改善高碳酸血症性ARDS患者的照护。
- 本研究为先导试验,样本量小(随机40例、分析35例),30天死亡率差异未达统计学显著(p=0.26)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current continuous kidney replacement therapy (CKRT) protocols ignore physiological renal compensation for hypercapnia. This study aimed to explore feasibility, safety, and clinical benefits of pCO2-adapted CKRT for hypercapnic acute respiratory distress syndrome (ARDS) patients with indication for CKRT.
METHODS: We enrolled mechanically ventilated hypercapnic ARDS patients (pCO2 > 7.33 kPa) receiving regional citrate anticoagulation (RCA) based CKRT in a prospective, randomized-controlled pilot-study across five intensive care units at the Charité-Universitätsmedizin Berlin, Germany. Patients were randomly assigned 1:1 to the control group with bicarbonate targeted to 24 mmol/l or pCO2-adapted-CKRT with target bicarbonate corresponding to physiological renal compensation. Study duration was six days. Primary outcome was bicarbonate after 72 h. Secondary endpoints included safety and clinical endpoints. Endpoints were assessed in all patients receiving treatment.
RESULTS: From September 2021 to May 2023 40 patients (80% male) were enrolled. 19 patients were randomized to the control group, 21 patients were randomized to pCO2-adapted-CKRT. Five patients were excluded before receiving treatment: three in the control group (consent withdrawal, lack of inclusion criteria fulfillment (n = 2)) and two in the intervention group (lack of inclusion criteria fulfillment, sudden unexpected death) and were therefore not included in the analysis. Median plasma bicarbonate 72 h after randomization was significantly higher in the intervention group (30.70 mmol/l (IQR 29.48; 31.93)) than in the control group (26.40 mmol/l (IQR 25.63; 26.88); p < 0.0001). More patients in the intervention group received lung protective ventilation defined as tidal volume < 8 ml/kg predicted body weight. Thirty-day mortality was 10/16 (63%) in the control group vs. 8/19 (42%) in the intervention group (p = 0.26).
CONCLUSION: Tailoring CKRT to physiological renal compensation of respiratory acidosis appears feasible and safe with the potential to improve patient care in hypercapnic ARDS.
TRIAL REGISTRATION: The trial was registered in the German Clinical Trials Register (DRKS00026177) on September 9, 2021 and is now closed.
参考来源
- Kunz JV, Hansmann H, Fähndrich M, et al. Standard vs. carbone dioxide adapted kidney replacement therapy in hypercapnic ARDS patients: a randomized controlled pilot trial (BigBIC). Crit Care. 2024. PMID: 38863072. doi:10.1186/s13054-024-04979-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。